Clinical trial recruitment, physician referrals, and site enrollment
Research backed answers for site owners, principal investigators, coordinators, and recruitment teams. Every number is linked to its original source.
Showing all 127 articles
How to get physicians to refer patients to your clinical trial
Physicians refer less than 0.2% of their patients into clinical trials, mostly because they lack study information and time. Here is how research sites close that gap and build a steady referral pipeline.
Why physicians rarely refer patients to clinical trials, and what fixes it
Physicians refer less than 0.2% of their patients into trials even though 90% are comfortable discussing research. The data points to information and time, not resistance. Here is what research sites can change.
What to include in a clinical trial referral letter to physicians
A clinical trial referral letter to physicians should fit on one page and answer what the study is, who qualifies, where it is, and how to refer. Here are the elements to include and what to leave out.
How to recruit more patients for a clinical trial at your site
Research sites recruit from three sources: their own records, advertising, and physician referrals. Physician referral is the most underused. Here is how to work all three with verified data behind each.
Why clinical trial sites miss enrollment targets
Tufts CSDD found 11% of sites enroll zero patients and 37% under enroll. Here is what the data says about why sites fall short and what a site can control to fix it.
What one day of enrollment delay costs a clinical trial
Tufts CSDD puts the direct cost of a Phase III trial at $55,716 per day and Phase II at $23,737. Here are the verified numbers, what changed from the old $4 million figure, and what it means for sites.
Can you pay physicians for clinical trial referrals? Finder's fees explained
Paying physicians solely for clinical trial referrals is unethical under the AMA Code, barred by WCG IRB, and can raise Anti Kickback concerns. Here is what the AMA, FDA, and IRBs say, and what sites can do instead.
What physicians need to know before referring a patient to a clinical trial
Before a physician refers a patient to your trial, they need five things: the study, the deciding criteria, the location, what the patient will go through, and one named contact. Here is why each matters.
How to follow up with physicians after they refer a patient to your trial
Nearly 30% of physicians never hear back from the site after referring a patient. Here is a follow up schedule that keeps referring physicians engaged, plus how to follow up with physicians who have not referred yet.
How to find specialists near your research site who treat your study population
Start from the study population, list the specialties that manage it, and pull every active physician within driving distance from the free CMS NPPES NPI Registry. Here is the step by step method.
Does outreach to referring physicians actually increase trial enrollment?
Published cases show physician outreach can become a site's top patient source, and one study shows a one time education push recruiting no one. Here is what separates outreach that works from outreach that does not.
Behind on enrollment: a recovery plan for clinical research sites
If your site is behind on enrollment, you are not alone: 37% of sites under enroll. Here is a four step recovery plan: diagnose the funnel, re mine records, add a physician referral source, and report weekly.
What it really costs to recruit one patient into a clinical trial
The $6,533 per patient figure is everywhere, but we could not trace it to a primary study. Here is what peer reviewed data shows about recruitment cost per patient, and how to calculate your own.
How to calculate recruitment ROI for a clinical research site
Recruitment ROI is the per patient revenue a channel produces, minus its cost, divided by its cost. Here is the formula, a worked example, and the mistakes that make channels look better or worse than they are.
Do physician outreach materials for a clinical trial need IRB approval?
FDA guidance says "dear doctor" and doctor to doctor letters are not direct advertising, even when they solicit subjects, while anything meant for patients is. Here is where the line sits and what to check with your IRB.
Physician referral strategy by therapeutic area
Which physicians should a site contact for an Alzheimer's, oncology, MASH, dermatology, respiratory, psychiatry, rheumatology, endocrinology, or migraine trial? A guide to referral sources by condition.
Which physicians refer patients to Alzheimer's clinical trials
Most dementia patients are first evaluated by community physicians. Here is what research says about who refers to Alzheimer's trials, what drives and blocks referrals, and why one time education is not enough.
Getting community oncologists to refer patients to oncology trials
About 85% of cancer patients are treated in community practices, but community programs enroll just 4.1% of patients in treatment trials versus 21.6% at NCI designated centers. Here is how sites close that gap.
Physician referrals vs Facebook ads for clinical trial recruitment
Online ads tend to be cheaper per enrollee and faster, while offline channels convert better. Here is what the research says about ads versus referrals, and how sites use both.
Recruiting for Parkinson's disease trials through neurologist referrals
80% of people with Parkinson's say they are likely to join research, yet fewer than 10% have enrolled in a study. Here is how sites use neurologists and movement disorder specialists to close that gap.
MASH clinical trial recruitment: which specialists to target
MASH trials face screen failure rates of 70 to 80%, mostly at the liver biopsy. Here is which physicians to reach and how better referrals reduce wasted screening.
Recruiting for psoriasis and atopic dermatitis trials through dermatologists
Dermatology trials depend on patients whose disease severity and prior treatments match the protocol. Here is which physicians to reach and what they need to send the right patients.
COPD trial enrollment through pulmonologist referrals
Many COPD patients in primary care are undiagnosed or diagnosed without spirometry, which drives screen failures. Here is why pulmonologists are the core referral source and how to use primary care well.
Recruiting for depression trials through psychiatrists and primary care
Primary care physicians prescribe 79% of antidepressants and see 60% of people treated for depression. Here is why depression trial outreach must include primary care alongside psychiatry.
Recruiting for rheumatoid arthritis trials through rheumatologists
Rheumatoid arthritis trials depend on disease activity and prior treatment history that rheumatologists track. Here is how to reach them and what to put in the referral summary.
Recruiting for obesity and type 2 diabetes trials through endocrinologists and primary care
Obesity and type 2 diabetes trials draw from a very large patient pool managed mostly in primary care. Here is which physicians to reach and how to prevent screen failures from medication and lab criteria.
How to build a physician referral network for your research site
A referral network turns local physicians into a steady patient source across studies. Here is a step by step method built on published case studies and Tufts CSDD referral research.
How sponsors can rescue an underperforming clinical trial site
With 37% of sites under enrolling and 11% enrolling no one, sponsors face the rescue decision often. Here are the options, from site support and physician outreach funding to protocol changes.
How better qualified referrals lower screen failure rates
The average screen failure rate is 36.3% and 57% in CNS trials. Here is how sites cut screen failures by improving what comes in: referrals from physicians who already know the deciding criteria.
Is direct mail to physicians effective for clinical trial recruitment?
In a randomized trial of 13,251 oncologists, mail drew an 11.8% response versus 4.5% for email. Here is what the evidence says about reaching physicians by mail, and how to combine it with digital follow up.
Where patients actually learn about clinical trials
Most people say they would ask their doctor first about clinical trials, but few are ever asked. Here is what CISCRP and other research show about how patients find trials, and what it means for sites.
How to grow a clinical research site: a practical playbook
Research sites grow by building a record sponsors can verify: enrollment, startup speed, and screen failure. Here is what the data says about site growth, why sponsors reuse sites, and a six step playbook.
How research sites get more studies from sponsors and CROs
Sponsors award more studies to sites that enroll reliably, start fast, and forecast honestly. Here is how sponsors choose, why new sites face a slower path, and what a site can do to win repeat work.
How sponsors and CROs select clinical trial sites
Sponsors shortlist sites with historical data and epidemiology, send feasibility questionnaires, then choose on patient access, past enrollment, and startup speed. Here is the process, how it evolved, and what it means for sites.
How to answer a feasibility questionnaire and win the study
Sponsors discount feasibility estimates because most are wrong. Here is how to build an enrollment estimate you can defend, document your patient access, and ask the questions that protect your site.
How to decide which clinical trials your site should take
Accepting a study you cannot fill hurts your record and your finances. Here is a checklist for choosing trials based on patient access, referral sources, budget terms, and staff capacity.
How to review a protocol for enrollment risk before you sign
Most enrollment problems are visible in the protocol before the first screen. Here is a six step review that maps criteria to patient sources, estimates screen failure, and flags red flags before you commit.
How to meet a clinical trial enrollment deadline
Most trials run late and more than a third of sites under enroll. Here is how to work backward from your deadline, measure your funnel weekly, and start every patient source before you need it.
How to reach first patient in faster after site activation
Site initiation to first patient in is the most variable part of study startup. Here is what Tufts CSDD benchmarks show and how sites use the startup period to have candidates waiting at activation.
The site performance metrics sponsors actually track
Sponsors judge sites on enrollment against target, time to first patient, screen failure, dropout, and data quality, and that history now travels between sponsors. Here are the metrics, the benchmarks, and how to improve them.
How to write a patient recruitment plan for a clinical trial
A recruitment plan names the target, the funnel assumptions, every patient source with expected yield and cost, screening capacity, and weekly metrics. Here is a section by section template built on published benchmarks.
How to engage nurses and nurse practitioners as clinical trial referral sources
Nurses refer a median of two patients a year and 45% never hear back from sites. With more than 461,000 licensed nurse practitioners in the US, here is how sites widen their referral network beyond physicians.
What physician referral outreach for a clinical trial costs
Physician referral outreach costs depend on how many physicians you reach, how often, and through which channels. Here is TrialNotice's published pricing, how it compares with doing it in house or buying ads, and the breakeven math.
Alternatives to patient recruitment vendors for small research sites
Full service recruitment vendors are not the only option. Here are five alternatives small research sites use, what each costs in time and money, and where each one works best.
How to choose a patient recruitment company for your research site
Recruitment companies differ in how they find patients, how they charge, and what they report. Here are the types, the pricing models, the questions to ask, and the red flags.
Should a research site market to physicians or directly to patients?
The protocol decides the balance. Here is a framework for choosing between physician outreach and direct to patient marketing based on diagnosis requirements, criteria complexity, prevalence, and approvals.
Enrollment strategies for principal investigators
Principal investigators open patient sources only a physician can: their own panel, peer relationships, and clinical credibility. Here are six strategies PIs use to lift enrollment.
How study coordinators get referrals from community doctors
Coordinators turn physician interest into actual referrals. Here are ten practical tips, from finding the right person in each office to confirming every referral within days.
How to negotiate a clinical trial budget as a site
Sites lose money on underfunded screen failures, recruitment, and slow payments. Here is how to build your own budget first, then negotiate the lines that decide whether a study makes money.
Independent research site vs joining a site network
Site networks offer contracting, sponsor relationships, and recruitment support in exchange for control and revenue. Here is how consolidation developed, what each path offers, and how independents compete.
Patient retention: keeping enrolled patients in the study
The average dropout rate in Phase II and III trials is 19.1%. Here is what the evidence actually says about retention tactics, and the practical steps sites use to keep patients through the last visit.
How to build a patient database for your research site
A research site's patient database is a list of people who agreed to be contacted about future studies. Here is how HIPAA applies, which sources feed it, what to record, and how to keep it current.
Clinical trial enrollment statistics: the complete reference
The verified numbers on site enrollment: how many sites miss targets, how enrollment concentrates, screen failure, dropout, activation, and protocol complexity. Every figure links to its original source.
Screen failure rates by therapeutic area: reference data
Published screen failure benchmarks: 36.3% across therapeutic areas, 57% in CNS, and 70 to 80% in MASH. Plus how to calculate your own rate and use it in budgets and forecasts.
Site activation and study startup benchmarks
Tufts CSDD benchmarks for study startup: 31.4 weeks from site identification to startup completion, 9.9 weeks faster at repeat sites, and only 62% of North American sites activating.
Clinical research site workforce statistics
Verified data on site staffing: turnover of 35 to 61%, 85% of departing staff going to sponsors and CROs, 17.5 training hours per study per month, and investigator turnover.
Clinical research site financial statistics
The verified numbers on site finances: underfunded screen failures, late invoices, operating capital, self funded recruitment, holdbacks, and the cost of trial delays.
Patient participation in clinical trials: key statistics
How patients find trials, who they trust, and how often they say yes: CISCRP, oncology, and Parkinson's data in one sourced reference.
Physician referral to clinical trials: key statistics
The data on physician and nurse referrals: referral rates, barriers, follow up gaps, setting and proximity effects, and how physicians respond to mail versus email.
Recruitment ROI calculator for research sites
Calculate the ROI and cost per randomized patient of any recruitment channel, including staff time and dropout. Free calculator for clinical research sites.
Revenue per patient calculator for research sites
Estimate what one enrolled patient is worth to your site after holdback timing and dropout. Free calculator for clinical research site owners and finance teams.
Enrollment forecast calculator for clinical trial sites
Turn your enrollment target into weekly randomizations, screens, and candidates, and see whether your current pace will hit the deadline. Free calculator for research sites.
Cost of delay calculator for clinical trials
Calculate the direct cost of an enrollment delay using Tufts CSDD's 2024 daily cost figures by phase, plus the published range for lost sales.
Feasibility estimate worksheet for research sites
Build an enrollment estimate for a feasibility questionnaire that you can defend: records, consent, screen failure, and referral sources, with the math shown.
Physician referral letter template for clinical trials
A copy ready, one page referral letter template for clinical trial sites, built on what research shows physicians need before they refer.
Patient recruitment plan template for clinical trial sites
A copy ready patient recruitment plan template for research sites: target, funnel assumptions, sources, approvals, budget, staffing, metrics, and contingency triggers.
Clinical trial budget negotiation checklist for sites
A 12 point checklist for negotiating a clinical trial budget: startup fees, screen failures, recruitment funding, overhead, payment terms, holdback, and invoiceables.
Why research sites are getting fewer studies, and what busy sites do differently
Fewer study opportunities is a real trend, not bad luck. Here is what changed in trial starts, sponsor behavior, and site selection, and what the sites still winning studies do differently.
Is a clinical research site still profitable? Margins, costs, and where money leaks
Site profits are under pressure: rising costs, underfunded screen failures, and self funded recruitment. Here is what the data shows, where margins leak, and what well run sites protect.
What buyers look for when they acquire a clinical research site
Site buyers pay for scale, backlog, margins, compliance, specialization, sponsor diversity, investigator depth, and proven patient access. Here is what each means and how to strengthen it.
Adding a therapeutic area: what it takes and what it pays
Live ClinicalTrials.gov counts of recruiting industry trials by therapeutic area, plus what a new area requires in investigators, staff, equipment, and patient access, and how to test demand first.
Starting a clinical research site: the first 12 months
What it takes to start a clinical research site: investigator commitments, staff, SOPs, systems, capital, getting found by sponsors, and building a patient source before the first study.
How private equity values a clinical research site
Clinical research sites are valued on EBITDA multiples: roughly 4x to 6x for small standalone sites and higher for scaled networks. Here is how multiples work, what moves them, and recent deals.
Should you sell your research site? Questions to ask first
Before selling a clinical research site to a network or private equity buyer, answer these questions about timing, value drivers, what you give up, and what you could fix first.
Late sponsor payments: how research sites protect cash flow
Nearly every site deals with late sponsor payments. Here is what the data shows, which contract terms help, how to chase overdue invoices, and how to keep cash flowing while you wait.
Why research site costs are rising, and where to cut safely
Most sites saw operating costs rise 6% or more in 2024, driven by salaries, protocol complexity, technology, and training. Here is where the costs come from and which cuts protect enrollment.
Operating capital for research sites: how much runway is enough
Sites at SCRS recommend at least three months of working capital. Here is why research sites need runway, how to calculate yours, and how to build it without starving operations.
Why research coordinators leave, and how sites keep them
Site turnover runs 35% to 61% a year, and 85% of departing staff go to sponsors and CROs. Here is why coordinators leave, what turnover costs a site, and what keeps them.
Sponsor training burden: where coordinator hours really go
Sites average 17.5 hours per study per month on training, and 65% of mandatory training is considered redundant. Here is the data, the industry efforts to cut it, and what sites can do now.
Why study startup takes so long, and where sites lose weeks
Study startup averages 31.4 weeks from site identification, and the contract and budget stages take the largest share. Here is where the time goes and which delays a site controls.
Hiring a research coordinator: pay, skills, and onboarding time
What to pay a clinical research coordinator, which skills matter, where to find candidates, and how to get a new coordinator productive without losing a study.
Invoiceables: what research sites forget to bill
Invoiceables are the variable or one time costs outside per visit payments: startup, pharmacy, amendments, monitor changes, storage, and closeout. Here are real published fee schedules and what to bill.
Why 40% of North American sites never activate, and how networks fix it
Tufts CSDD puts the North American site activation rate at 62%. Here is why sites stall in contracting, budgets, and IRB approval, and how site networks and prepared independents activate faster.
Standardizing patient recruitment across a site network
Networks win on consistency, but recruitment is local. Here is how to build a central recruitment playbook that each location runs with its own physicians, records, and community.
Integrating an acquired research site: the first 90 days
Acquired sites lose value when staff leave, studies stall, and referral relationships fade. Here is a 90 day integration plan that protects people, studies, sponsors, and patient sources.
The KPIs site network leaders track
The metrics that show whether a site network is healthy: activation, enrollment against target, screen failure, retention, startup time, quality, staffing, and patient source mix.
When a sponsor goes silent after feasibility
Most sites have answered a feasibility questionnaire and never heard back. Here is why sponsors go quiet, how long to wait, how to follow up, and how to be chosen next time.
What a pre study visit really assesses
A pre study or site qualification visit checks investigators, staff, facilities, systems, and above all whether the site can enroll. Here is what sponsors look at and how to prepare.
Rescue studies: how sites get them
When a trial falls behind, sponsors add rescue sites that can start fast and enroll immediately. Here is how rescue studies work, what sponsors need, and how to be the site they call.
Building a strong relationship with your CRA
Your clinical research associate shapes how the sponsor sees your site. Here is how to make monitoring visits smooth, handle CRA turnover, and turn your CRA into an advocate.
Sponsor scorecards and how to improve yours
Sponsors score sites on enrollment, startup speed, data quality, and compliance, and that history decides future selection. Here is what gets measured and how to move each number.
Site performance data that follows you between sponsors
Sponsors share site and investigator performance through the Investigator Databank and IQVIA's Data Query System. Here is what is shared, how sponsors use it, and how to view your own record.
How to improve diversity in clinical trial enrollment at your site
Where FDA's Diversity Action Plan requirement stands, why enrollment gaps persist, and the practical steps sites use to reach patients from communities underrepresented in research.
Community outreach for clinical trial recruitment: what works
Community events, partnerships, and local organizations can outperform passive recruitment. Here is what the evidence shows, which partners work, and how to run outreach a site can sustain.
Social media recruitment for research sites: a practical guide
Social media can reach patients cheaply, but Meta's 2025 health advertiser restrictions changed how campaigns optimize. Here is what still works, what IRBs require, and how to measure real results.
Google Ads for clinical trial recruitment
Google allows clinical trial recruitment ads in the US with limits: no prescription drug promotion, no implied safety, and no health based personalized targeting. Here is how to run search ads within the rules.
SEO for clinical research sites: study pages that get found
How research sites get found by patients, physicians, and sponsors through Google and AI assistants: study pages, condition pages, what FDA allows without IRB review, and what to measure.
Adding clinical trials to a medical practice: the business case
What it takes for a physician practice to start running clinical trials: the investigator commitment, staff, capital, revenue model, and the advantages practices have over standalone sites.
How many studies should a site run at once?
There is no universal number. Here is how to calculate your site's real capacity from coordinator hours, training load, visit volume, and patient overlap, and the warning signs you have taken on too much.
Opening a second research site location: when it makes sense
A second location can double patient access, or double overhead. Here is how to decide: demand, investigators, market data, staffing, and a patient pipeline for the new site.
Medical device trials: what sites need to know
Device trials follow different rules than drug trials: significant risk vs nonsignificant risk studies, IDE requirements, the IRB's role, and how device studies change site operations.
Decentralized and hybrid trials: what they mean for sites
FDA's September 2024 guidance on decentralized trial elements keeps investigators responsible for oversight and consent. Here is what changes for sites, what does not, and the opportunity in hybrid studies.
Patient stipends and travel reimbursement: what sites can offer
What FDA allows when paying clinical trial participants: travel reimbursement, prorated payment for time, small completion bonuses, and what IRBs look for. Plus how payment affects enrollment and retention.
Coverage analysis: what sites need to know
A coverage analysis decides, before enrollment, which study procedures are billed to the sponsor and which to insurance under Medicare's clinical trial policy (NCD 310.1). Here is how it works and why it protects revenue.
Central IRB vs local IRB: what sites need to know
Federally funded multisite research has required a single IRB since 2020, and FDA plans to finalize a single IRB rule for FDA regulated trials. Here is where things stand and what it means for site startup.
Preparing for an FDA inspection at your site
FDA ran 681 clinical investigator inspections in fiscal 2023. Here are the most common findings, how to stay inspection ready, and what to do when FDA calls.
Automating physician outreach without losing the personal touch
Physician outreach fails when it depends on one busy coordinator. Here is which parts to automate, which must stay personal, and what the data says about mail, email, and follow up.
Protocol amendments: what they cost sites and how to renegotiate
82% of Phase III protocols now have at least one substantial amendment, averaging 3.5 each. Here is what amendments cost sites in time and money, and how to recover it.
Record retention: what sites must keep, for how long, and who pays
FDA requires investigators to keep records for 2 years after marketing approval or study discontinuation, but sponsor contracts often require longer. Here is what to keep, how long, and how to get storage paid for.
Adding sub investigators to grow site capacity
Sub investigators extend a PI's reach, reduce single physician risk, and help sites take more studies. Here is what the role involves, how to recruit and train them, and why buyers and sponsors value them.
Partnering with a health system as an independent site
Health systems have patients, specialists, and data; independent sites have speed and research operations. Here is how partnerships work, what each side gains, and what to settle before signing.
Protocol deviations: why they are rising and how sites reduce them
Phase III protocols average 119 deviations, involving about a third of enrolled patients, and over 40% in oncology. Here is what drives deviations and the practical steps that prevent them.
Site initiation visit checklist
A practical checklist for the site initiation visit: documents, people, facilities, systems, product, and the enrollment plan that turns activation into a first patient.
Phone prescreening: scripts and compliance
Phone prescreening filters inquiries before a screening visit. Here is how to write a script around the deciding criteria, what privacy and IRB rules apply, and how to handle each call.
Monitoring visits and remote monitoring: making them faster and smoother
FDA has endorsed risk based monitoring since 2013, blending on site, remote, and centralized review. Here is what each means for sites and how to make every monitoring visit efficient.
Profit per study: a simple site P&L model
A study level profit and loss model for research sites: revenue lines, direct costs, overhead, and the enrollment level where a study breaks even. Includes a worked example.
Overhead and indirect rates for independent research sites
Academic centers apply published indirect rates to industry studies, such as 39% at Penn. Here is how independent sites calculate their own overhead rate and build it into every budget.
How to recruit breast cancer patients for clinical trials at your site
Breast cancer trial recruitment data: 923 recruiting US studies, 321,910 new diagnoses expected in 2026, where trials concentrate, and how sites win physician referrals.
How to recruit lung cancer patients for clinical trials
Lung cancer trial recruitment data: 876 recruiting US studies, 229,410 new cases expected in 2026, the most industry funded trials of any cancer here, and who refers patients.
How to recruit prostate cancer patients for clinical trials
Prostate cancer trial recruitment data: 333,830 new cases expected in 2026, 598 recruiting US studies, and why urologists are the referral source most sites miss.
How to recruit heart failure patients for clinical trials
Heart failure trial recruitment data: 6.7 million US adults with heart failure, 325 recruiting US studies, a large device trial share, and which physicians to reach.
How to recruit chronic kidney disease patients for clinical trials
CKD trial recruitment data: about 37 million US adults with CKD, 87% unaware, 180 recruiting US studies, and why nephrologists and primary care hold the patients.
How to recruit ulcerative colitis and Crohn's patients for clinical trials
IBD trial recruitment data: 2.39 million Americans with IBD, 156 recruiting US studies, a high industry share, and why gastroenterology practices drive enrollment.
How to recruit multiple sclerosis patients for clinical trials
MS trial recruitment data: nearly 1 million US adults with MS, 157 recruiting US studies, CNS screen failure benchmarks, and how sites reach neurologists.
How to recruit migraine patients for clinical trials
Migraine trial recruitment data: 20.7% of US women and 9.7% of men affected, only 72 recruiting US studies, and why primary care and neurology both matter.
How to recruit asthma patients for clinical trials
Asthma trial recruitment data: 27.8 million Americans with current asthma, 129 recruiting US studies, and which allergists, pulmonologists, and pediatricians to reach.
How to recruit lupus patients for clinical trials
Lupus trial recruitment data: about 204,295 Americans with SLE, 93 recruiting US studies with a majority industry funded interventional share, and how sites reach rheumatologists.